Share on StockTwits

OraSure Technologies (NASDAQ:OSUR) is set to release its Q214 earnings data on Wednesday, August 6th. Analysts expect OraSure Technologies to post earnings of ($0.04) per share and revenue of $26.21 million for the quarter. OraSure Technologies has set its Q2 guidance at ($0.10)-($0.09) EPS.Parties interested in registering for the company’s conference call can do so using this link.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.28 million. During the same quarter in the previous year, the company posted ($0.18) earnings per share. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, analysts expect OraSure Technologies to post $-0.17 EPS for the current fiscal year and $0.04 EPS for the next fiscal year.

OraSure Technologies (NASDAQ:OSUR) opened at 8.23 on Tuesday. OraSure Technologies has a 1-year low of $4.17 and a 1-year high of $9.00. The stock’s 50-day moving average is $8.43 and its 200-day moving average is $7.25. The company’s market cap is $459.6 million.

A number of research firms have recently commented on OSUR. Analysts at Zacks upgraded shares of OraSure Technologies from a “neutral” rating to an “outperform” rating in a research note on Tuesday, June 24th. They now have a $9.20 price target on the stock. On the ratings front, analysts at Jefferies Group reiterated a “buy” rating on shares of OraSure Technologies in a research note on Thursday, June 12th. They now have a $10.00 price target on the stock, up previously from $9.00. Finally, analysts at Raymond James raised their price target on shares of OraSure Technologies from $8.50 to $9.00 in a research note on Thursday, June 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. OraSure Technologies presently has an average rating of “Buy” and an average target price of $9.70.

OraSure Technologies, Inc, is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company’s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.